Loading
A phase 1/2 trial of Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Cho Pharma Inc., active and no longer recruiting.
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05950165 by Cho Pharma Inc., with 37 participants planned, started 2020-01-15 and due to reach its primary completion in 2026-12-23. Interventions recorded: CHO-H01, CHO-H01 at RP2D, Lenalidomide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares PROTACs & molecular glues (targeted protein degradation), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares PROTACs & molecular glues (targeted protein degradation), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/